Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
P/E ratio for Biocon Limited (BIOCON.NS)
P/E ratio as of 2023: 31.54
According to Biocon Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 31.54. At the end of 2022 the company had a P/E ratio of 53.21.
P/E ratio history for Biocon Limited from 2003 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 31.54 |
| 2022 | 53.21 |
| 2021 | 61.65 |
| 2020 | 65.55 |
| 2019 | 42.82 |
| 2018 | 40.49 |
| 2017 | 94.81 |
| 2016 | 36.31 |
| 2015 | 10.59 |
| 2014 | 18.87 |
| 2013 | 20.13 |
| 2012 | 11.07 |
| 2011 | 13.84 |
| 2010 | 18.36 |
| 2009 | 18.87 |
| 2008 | 29.66 |
| 2007 | 8.96 |
| 2006 | 23.47 |
| 2005 | 24.47 |
| 2004 | 19.52 |
| 2003 | 29.57 |